---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-115069"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:28:26.796907+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Carisma Q3 net loss $12.7M; cash $26.9M; CT-0525 initial data expected Q1 2025

## Summary
- Net loss of $12.7M in Q3 2024 vs $21.4M in Q3 2023; R&D expenses fell to $11.3M from $19.6M.
- Cash and equivalents $26.9M as of Sep 30, 2024, down from $40.4M at Jun 30; expected runway into Q3 2025.
- Phase 1 CT-0525 (HER2 CAR-Monocyte) initial data for Cohorts 1 and 2 expected Q1 2025; protocol amended for repeat dosing with pembrolizumab.
- Expanded Moderna collaboration to include two autoimmune targets; retains rights beyond those.
- Liver fibrosis development candidate nomination expected Q1 2025; preclinical data to be presented at AASLD.

## SEC filing metadata
- accession: 0001104659-24-115069
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465924115069/0001104659-24-115069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465924115069/tm2426977d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-115069
- JSON: https://secwatch.observer/filing/0001104659-24-115069.json
- Plain text: https://secwatch.observer/filing/0001104659-24-115069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.